Zenas BioPharma, Inc.
ZBIO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|
| Revenue | $5,000 | $50,000 | $0 |
| % Growth | -90% | – | – |
| Cost of Goods Sold | $139,139 | $0 | $61,689 |
| Gross Profit | -$134,139 | $50,000 | -$61,689 |
| % Margin | -2,682.8% | 100% | – |
| R&D Expenses | $139,139 | $60,033 | $62,689 |
| G&A Expenses | $28,849 | $17,114 | $12,810 |
| SG&A Expenses | $29,749 | $17,114 | $13,510 |
| Sales & Mktg Exp. | $900 | $0 | $700 |
| Other Operating Expenses | -$139,139 | $10,000 | -$61,689 |
| Operating Expenses | $29,749 | $87,147 | $14,510 |
| Operating Income | -$163,888 | -$37,147 | -$76,199 |
| % Margin | -3,277.8% | -74.3% | – |
| Other Income/Exp. Net | $7,329 | $324 | -$43,083 |
| Pre-Tax Income | -$156,559 | -$36,823 | -$119,282 |
| Tax Expense | $429 | $301 | $0 |
| Net Income | -$156,988 | -$37,124 | -$119,282 |
| % Margin | -3,139.8% | -74.2% | – |
| EPS | -3.76 | -0.97 | -3.11 |
| % Growth | -287.6% | 68.8% | – |
| EPS Diluted | -3.76 | -0.97 | -3.11 |
| Weighted Avg Shares Out | 41,785 | 38,317 | 38,317 |
| Weighted Avg Shares Out Dil | 41,785 | 38,317 | 38,317 |
| Supplemental Information | – | – | – |
| Interest Income | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 |
| Depreciation & Amortization | $137 | $113 | $78 |
| EBITDA | -$163,751 | -$27,034 | -$75,121 |
| % Margin | -3,275% | -54.1% | – |